The U.S. Supreme Court denied Agilent Technologies’ request to review invalidation of two CRISPR-related patents tied to chemical modifications of guide RNAs (gRNAs), effectively ending a multi-year IP dispute with gene-editing company Synthego. The decision leaves in place a June 2025 Federal Circuit ruling upholding USPTO PTAB determinations that deemed the claims unpatentable. With the appeals chain exhausted, the ruling removes a barrier for use of the contested gRNA modification approaches in CRISPR-enabled research and therapeutic development. For platform developers and therapeutic innovators, the outcome is a concrete IP signal that can shift licensing strategies, freedom-to-operate calculations, and development roadmaps.